Skip to main content

Laura Jean Havrilesky, MD

Laura Havirlesky, MD
Professor of Obstetrics and Gynecology
Campus Mail: 25172 Morris Bldg, Durham, NC 27710
Phone: (919) 684-0188
Email: havri001@mc.duke.edu

I am interested in using health economic models to inform decisions related to gynecologic cancers. Specific models have addressed the decision to administer intraperitoneal chemotherapy for newly diagnosed advanced ovarian cancer following optimal cytoreduction, the choice of chemotherapy regimen for recurrent platinum-sensitive ovarian cancer, and the exploration of screening strategies for ovarian cancer. The ovarian cancer screening model examines the effects of test cost, sensitivity, specificity, and screen frequency on ovarian cancer mortality, the lifetime false positive rate of testing, the positive predictive value of the test, and its cost effectiveness. This type of model is potentially useful in informing the design trials of novel screening tests for ovarian cancer. I am also conducting a prospective study to quantify the effects of screening for, diagnosis of, and treatment for ovarian cancer on the quality of life of women.

Education and Training

  • Residency, Obstetrics And Gynecology, Duke University, 1995 - 1999
  • M.D., Duke University, 1995

Research

I am interested in using health economic models to inform decisions related to gynecologic cancers. Specific models have addressed the decision to administer intraperitoneal chemotherapy for newly diagnosed advanced ovarian cancer following optimal cytoreduction, the choice of chemotherapy regimen for recurrent platinum-sensitive ovarian cancer, and the exploration of screening strategies for ovarian cancer.

The ovarian cancer screening model examines the effects of test cost, sensitivity, specificity, and screen frequency on ovarian cancer mortality, the lifetime false positive rate of testing, the positive predictive value of the test, and its cost effectiveness. This type of model is potentially useful in informing the design trials of novel screening tests for ovarian cancer. I am also conducting a prospective study to quantify the effects of screening for, diagnosis of, and treatment for ovarian cancer on the quality of life of women. 

Publications

Fader, AN, Nagel, C, Axtell, AE, Zanotti, KM, Kelley, JL, Moore, KN, Secord, AA, Walsh, CS, Huh, WK, Gehrig, PA, Gibbons, H, Rose, PG, Havrilesky, LJ, Tuller, E, Drake, RD, Bottsford-Miller, J, O'Malley, DM, and UPSC Consortium, . "Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes." Gynecol Oncol 112, no. 3 (March 2009): 558-562.

Full Text

Neubauer, NL, Havrilesky, LJ, Calingaert, B, Bulusu, A, Bernardini, MQ, Fleming, ND, Bland, AE, and Secord, AA. "The role of lymphadenectomy in the management of preoperative grade 1 endometrial carcinoma." Gynecol Oncol 112, no. 3 (March 2009): 511-516.

Full Text

Bland, AE, Calingaert, B, Secord, AA, Lee, PS, Valea, FA, Berchuck, A, Soper, JT, and Havrilesky, L. "Relationship between tamoxifen use and high risk endometrial cancer histologic types." Gynecol Oncol 112, no. 1 (January 2009): 150-154.

Full Text

Havrilesky, LJ, Sanders, GD, Kulasingam, S, and Myers, ER. "Reducing ovarian cancer mortality through screening: Is it possible, and can we afford it?." Gynecol Oncol 111, no. 2 (November 2008): 179-187.

Full Text

Havrilesky, LJ, Secord, AA, Darcy, KM, Armstrong, DK, Kulasingam, S, and Gynecologic Oncology Group, . "Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study." J Clin Oncol 26, no. 25 (September 1, 2008): 4144-4150.

Full Text

Havrilesky, LJ, Whitehead, CM, Rubatt, JM, Cheek, RL, Groelke, J, He, Q, Malinowski, DP, Fischer, TJ, and Berchuck, A. "Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence." Gynecol Oncol 110, no. 3 (September 2008): 374-382.

Full Text

Lee, PS, Bakelaar, R, Fitpatrick, CB, Ellestad, SC, Havrilesky, LJ, and Alvarez Secord, A. "Medical and surgical treatment of placenta percreta to optimize bladder preservation." Obstet Gynecol 112, no. 2 Pt 2 (August 2008): 421-424.

Full Text

Linkov, F, Yurkovetsky, Z, Taioli, E, Havrilesky, LJ, Maxwell, GL, and Lokshin, A. "Endometrial cancer: multiplexed Luminex approaches for early detection." Expert Opin Med Diagn 2, no. 5 (May 2008): 527-537.

Full Text

Kirkpatrick, JP, Rabbani, ZN, Bentley, RC, Hardee, ME, Karol, S, Meyer, J, Oosterwijk, E, Havrilesky, L, Secord, AA, Vujaskovic, Z, Dewhirst, MW, and Jones, EL. "Elevated CAIX Expression is Associated with an Increased Risk of Distant Failure in Early-Stage Cervical Cancer. (Published online)" Biomark Insights 3 (February 1, 2008): 45-55.

Scholars@Duke

Jr, RJM, Alvarez, RD, Armstrong, DK, Boston, B, Chen, L-M, Copeland, L, Fowler, J, Gaffney, DK, Gershenson, D, Greer, BE, Grigsby, PW, Havrilesky, LJ, Johnston, C, Lancaster, JM, Lele, S, Matulonis, U, O'Malley, D, Ozols, RF, Remmenga, SW, Sabbatini, P, Schink, J, and Teng, N. "Ovarian cancer." JNCCN Journal of the National Comprehensive Cancer Network 6, no. 8 (2008): 766-794.

Scholars@Duke

Pages